🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHas anyone dealt with mash resolution without worsening fibrosis? Page 2

Has anyone dealt with mash resolution without worsening fibrosis?

KevinCompounds Thu, Oct 31, 2024 at 11:40 AM 45 replies 2,606 viewsPage 2 of 9
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
Oct 31, 2024 at 8:12 PM#6
PharmacoVig_BOS said:
Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 332 dB/m (moderate steatosis) and stiffness 10.8 kPa (possible…

Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Baseline: "Moderate hepatic steatosis, liver span 17.2cm, echogenic texture consistent with fat infiltration"
Month 8: "Mild steatosis, liver span 15.8cm, improved echogenicity"
Month 14: "Minimal to no steatosis, normal liver span 14.5cm, normal echotexture"

My liver literally shrank and de-fattened. The ultrasound tech said she's seen this pattern increasingly in GLP-1 patients and it's remarkable how consistently the fatty liver resolves.

43 13pam_stl, wei_SG, cory_ATX and 40 others
Reply Quote Save Share Report
quinn_sf
Member
489
2,123
Jun 2024
San Francisco, CA
Oct 31, 2024 at 11:34 PM#7
KevinCompounds said:
ALT was mildly raised at baseline, normalised at month five, and I now have no idea whether anything happened to the fibrosis that actually matters.

NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy. The Phase 2b data for semaglutide showed 59% NASH resolution (vs 17% placebo) with 43% achieving fibrosis improvement[1].

Mechanism: GLP-1R activation reduces hepatic lipogenesis, increases fatty acid oxidation, reduces hepatic inflammation, and may directly reduce hepatic stellate cell activation (fibrosis pathway).

With resmetirom (thyroid hormone receptor agonist) recently approved for NASH, the field is evolving rapidly. Combination approaches (GLP-1 + resmetirom) are being explored.

References:
[1] Newsome PN, et al. N Engl J Med. 2021;384(12):1113-1124.
42 12Dr.PathRoch, mona_PHX, andrew_nyc and 39 others
Reply Quote Save Share Report
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
Nov 1, 2024 at 2:56 AM#8
Dr.LipidDallas said:
Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

There is a second half to this that has not been said yet. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

Ask again with the specifics and you will get a better answer than this one.

Last edited: Nov 1, 2024 at 8:56 AM
41 11tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 38 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Nov 1, 2024 at 6:18 AM#9

Following on from MASHdoc_SA — and this may be the naive question:

How long did you give it before you decided it was working?

40 10SaraMom3, Dr.MetabolicMD, RetaRick_CA and 37 others
Reply Quote Save Share Report
KevinCompounds
VIP Member
5,432
18,234
Dec 2023
Nevada
Nov 1, 2024 at 10:28 PM#10

Reporting back.

For the archive: it took about six weeks rather than the two I expected, and the difference between those two numbers was the whole of my problem.

36 9NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 33 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register